APA (7th ed.) Citation

CS, K., M, S., M, S., TJ, L., P, F., ES, H., . . . DS, P. (2024). Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious diseases and therapy, 13(10), 2105. https://doi.org/10.1007/s40121-024-01007-z

Chicago Style (17th ed.) Citation

CS, Kraft, et al. "Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI." Infectious Diseases and Therapy 13, no. 10 (2024): 2105. https://doi.org/10.1007/s40121-024-01007-z.

MLA (9th ed.) Citation

CS, Kraft, et al. "Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI." Infectious Diseases and Therapy, vol. 13, no. 10, 2024, p. 2105, https://doi.org/10.1007/s40121-024-01007-z.